The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

Rather than offering patients a new molecule, Uzedy’s breakthrough is tied to its method of delivery. Developed with a technology Teva licensed from Medincell called SteadyTeq, Uzedy offered the ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

Teva Pharmaceutical Industries Limited develops ... associated with Huntington’s disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder ...

Teva’s new chief executive Richard Francis highlighted the recent FDA approval of long-active schizophrenia therapy Uzedy (risperidone) as a key part of the company’s new “pivot to growth ...

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...